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Three-part clinical question:
Patients: Children (≤16 years) admitted to a paediatric intensive care unit (ICU) who were expected to require mechanical ventilation and vasoactive drugs for more than 12 hours. Subgroup analysis was made between cardiac surgery patients and non-cardiac surgery patients. Intervention: Patients were randomised to receive either tight glycaemic control (target blood glucose range 4-7 mmol/L) or conventional glycaemic control (target blood glucose <12 mmol/L).
Outcomes:
The primary outcomes were the number of days alive and free from mechanical ventilation at 30 days following randomisation. The secondary outcomes were measured at the time of discharge from ICU (or at 30 days if admitted for >30 days) and at 12 months following randomisation. At discharge, length of stay on ICU was recorded, along with vital status, duration of mechanical ventilation, use of vasoactive drugs, the need for renal replacement therapy, the use of antibiotics for more than 10 days, the number of red cell transfusions, the Paediatric Logistic Organ Dysfunction score, readmission rates to ICU, hospital length of stay and estimated patient costs. At 12 months, the length of stay in ICU and hospital (including any readmissions), vital status and cost to the hospital and community health services were recorded.
The study design:
A parallel-group randomised, controlled trial (RCT).
The study patients: A total of 1,369 patients were recruited from 13 paediatric ICU units in England over three years and four months; 694 patients were randomised to the tight glycaemic control group and 675 patients were randomised to receive conventional glycaemic control; 60% of patients had undergone cardiac surgery. Inclusion criteria: Patients aged between 36 weeks (corrected gestational age) and 16 years admitted to a paediatric ICU with an arterial catheter in situ, mechanically ventilated and receiving vasoactive drugs, with an expected duration of more than 12 hours. Exclusion criteria: Patients were excluded if they had been in ICU for more than five days, had already participated in this trial, were known to have diabetes mellitus or a suspected/confirmed inborn error of metabolism, or if treatment withdrawal was being considered.
Results
There was no significant difference in the number of days that children were alive and free from mechanical ventilation at 30 days following randomisation between the two groups. Secondary outcomes were similar between the two groups; however there was a lower requirement for renal replacement therapy in the tight glycaemic control group.
In the non-cardiac subgroup at 12-month follow-up, tight glycaemic control was associated with a shorter length of stay in hospital (on average 13.5 days less). Mean costs were lower by approximately £8,000 per patient ($13,120). However, there
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In paediatric intensive care (≤16 years of age), tight glycaemic control is not associated with a mortality benefit. There is a higher risk of significant hypoglycaemia. In cardiac intensive care unit patients, this hypoglycaemia is associated with a significant increase in mortality.
Level of evidence: 2B (CEBM).
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Outcomes:
Tight glycaemic Conventional glycaemic control (n=694) control (n=675)
Primary:
No. of days alive and free from ventilation at 30 days -mean±SD 23.6±0.3 23.2±0.3
